Workflow
重药控股:上半年扣非净利润同比预增14.39%-28.12% 拟8000万元至1亿元回购公司股份

Group 1 - The company expects to achieve a net profit of 250 million to 280 million yuan for the first half of 2025, representing a year-on-year growth of 14.39% to 28.12% after deducting non-recurring gains and losses [1] - The forecasted net profit attributable to shareholders is estimated to be between 260 million and 300 million yuan, with a year-on-year increase of 9.2% to 26% [1] - The company plans to repurchase shares using its own funds and a special loan for stock repurchase, with a total amount not less than 80 million yuan and not exceeding 100 million yuan [1] Group 2 - The repurchase price will not exceed 6.6 yuan per share, with an estimated repurchase quantity of approximately 15.15 million shares, accounting for about 0.88% of the current total share capital [2] - The estimated repurchase quantity could be around 12.12 million shares, representing about 0.70% of the total share capital, based on the lower limit of the repurchase funds [2] - The funding for the repurchase will come from the company's own funds and a special loan, with a commitment from China Everbright Bank to provide up to 90 million yuan for the stock repurchase [2]